# Triple-G Agonist

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/triple-g-agonist
Canonical HTML page: https://gethealthbrief.com/entity/triple-g-agonist

## Timeline

- **2027**: Regulatory Submissions — Expected window for the first triple-agonist drug applications to the FDA.
- **2026-02-24**: Novo Triple-G Phase 2 — Novo Nordisk reports nearly 20% weight loss at 26 weeks.
- **2026**: Phase 3 Expansion — Anticipated start of Novo Nordisk's pivotal late-stage clinical program.
- **2023-Q2**: Lilly Retatrutide Phase 2 — Eli Lilly releases data showing 17.5% weight loss at 24 weeks.

## Recent coverage (1 stories)

### Novo Nordisk Triple-G Agonist Challenges Eli Lilly in Obesity Market
2026-02-24 12:06:06 · Sentiment: Neutral · Impact: 7/10 · Sources: 2

Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second.
Full story: https://gethealthbrief.com/story/novo-nordisk-triple-g-obesity-trial-results

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.